The Spinocerebellar Ataxia (SCA) drugs in development market research report provides comprehensive information on the therapeutics under development for Spinocerebellar Ataxia (SCA), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Spinocerebellar Ataxia (SCA). Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Spinocerebellar Ataxia (SCA) and features dormant and discontinued products.

GlobalData tracks 38 drugs in development for Spinocerebellar Ataxia (SCA) by 37 companies/universities/institutes. The top development phase for Spinocerebellar Ataxia (SCA) is preclinical with 19 drugs in that stage. The Spinocerebellar Ataxia (SCA) pipeline has 31 drugs in development by companies and seven by universities/ institutes. Some of the companies in the Spinocerebellar Ataxia (SCA) pipeline products market are: Anima Biotech, Blade Therapeutics and Ionis Pharmaceuticals.

The key targets in the Spinocerebellar Ataxia (SCA) pipeline products market include Ataxin 3 (Machado Joseph Disease Protein 1 or Spinocerebellar Ataxia Type 3 Protein or SCA3 or ATXN3 or EC 3.4.19.12), Ataxin 1 (Spinocerebellar Ataxia Type 1 Protein or SCA1 or ATX1 or ATXN1), and Ataxin 2 (Spinocerebellar Ataxia Type 2 Protein or Trinucleotide Repeat Containing Gene 13 Protein or ATXN2).

The key mechanisms of action in the Spinocerebellar Ataxia (SCA) pipeline product include Ataxin 3 (Machado Joseph Disease Protein 1 or Spinocerebellar Ataxia Type 3 Protein or SCA3 or ATXN3 or EC 3.4.19.12) Inhibitor with seven drugs in Phase II. The Spinocerebellar Ataxia (SCA) pipeline products include seven routes of administration with the top ROA being Oral and seven key molecule types in the Spinocerebellar Ataxia (SCA) pipeline products market including Small Molecule, and Antisense Oligonucleotide.

Spinocerebellar Ataxia (SCA) overview

Spinocerebellar ataxias (SCAs) are a group of inherited conditions that affect the brain and spinal cord causing progressive difficulty with coordination. Symptoms include poor coordination, unsteady walk and a tendency to stumble, change in speech, and difficulty swallowing.

For a complete picture of Spinocerebellar Ataxia (SCA)’s pipeline drug market, buy the report here.

This content was updated on 25 January 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.